The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Risk of recurrence and survival after relapse in patients with Ewing sarcoma
Abstract
Background: The prognosis in patients with relapsed Ewing sarcoma is unfavorable. Our investigation identifies factors predicting for the outcome following relapse. Procedure: We analyzed type of relapse, time to relapse and overall survival after relapse (OSr) in 714 patients with first recurrence. All patients had been treated within the Cooperative Ewing Sarcoma Studies (CESS) 81 or 86, or the European Intergroup CESS (EICESS 92). OSr time was calculated from diagnosis of first relapse to last follow‐up or death. Results: Median follow‐up time from diagnosis of primary disease was 2.2 years (mean = 4.0; range: 0.2–24.9). Relapse sites were local in 15%, combined local and systemic in 12%, and systemic in 73%. Among patients with a localized primary tumor, 20% relapsed locally, while 12% showed combined and 68% systemic relapse. When the primary disease was disseminated, 82% developed systemic, 13% combined, and 5% local relapse. Five‐year OSr was 0.13 (SE = 0.01). Outcome following local relapse, with a 5‐year survival rate of 0.24 (P < 0.001), was superior to outcome after systemic or combined recurrence. Five‐year OSr was 0.07 (SE = 0.01) in patients who relapsed 0–2 years after the diagnosis of primary disease, as compared to a 5‐year OSr of 0.29 (SE = 0.03) when relapse occurred later. Conclusions: 5‐year OSr in Ewing sarcoma is poor (<0.2). Prognostically favorable factors are: late onset (>2 years) and strictly localized relapse. Pediatr Blood Cancer 2011; 57: 549–553. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Cotterill, S. J., Ahrens, S., Paulussen, M., Jürgens, H. F., Voûte, P. A., Gadner, H., & Craft, A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3108 · Cited by 1,040
Self-citationEsiashvili, N., Goodman, M., & Marcus, R. B. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31816e22f3 · Cited by 582
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
Ladenstein, R., Pötschger, U., Le Deley, M. C., Whelan, J., Paulussen, M., Oberlin, O., van den Berg, H., Dirksen, U., Hjorth, L., Michon, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9864 · Cited by 540
Self-citationLocalized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1818 · Cited by 445
Self-citationJürgens, H., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voûte, T., Winkelmann, W., Winkler, K., et al. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m · Cited by 417
Self-citationSchuck, A., Ahrens, S., Paulussen, M., Kuhlen, M., Könemann, S., Rübe, C., Winkelmann, W., Kotz, R., Dunst, J., Willich, N., et al. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03797-5 · Cited by 348
Self-citationPrimary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies
Paulussen, M., Ahrens, S., Burdach, S., Craft, A., Dockhorn-Dworniczak, B., Dunst, J., Fröhlich, B., Winkelmann, W., Zoubek, A., & Jürgens, H. (1998) · Annals of Oncology · doi:10.1023/a:1008208511815 · Cited by 317
Self-citationPaulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5720 · Cited by 263
Self-citationPaulussen, M., Ahrens, S., Craft, A. W., Dunst, J., Fröhlich, B., Jabar, S., Rübe, C., Winkelmann, W., Wissing, S., Zoubek, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3044 · Cited by 249
Self-citationBielack, S. S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., Kevric, M., Jundt, G., Kühne, T., Maas, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2305 · Cited by 238
Self-citationSurvival After Recurrence of Ewing’s Sarcoma Family of Tumors
Barker, L. M., Pendergrass, T. W., Sanders, J. E., & Hawkins, D. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.105 · Cited by 219
Leavey, P. J., Mascarenhas, L., Marina, N., Chen, Z., Krailo, M., Miser, J., Brown, K., Tarbell, N., Bernstein, M. L., Granowetter, L., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21618 · Cited by 204
Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., Eckhardt, S. G., Eid, J. E., Greig, G., Habben, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3220 · Cited by 196
Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience
Casey, D. A., Wexler, L. H., Merchant, M. S., Chou, A. J., Merola, P. R., Price, A. P., & Meyers, P. A. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22206 · Cited by 190
Rodriguez‐Galindo, C., Billups, C. A., Kun, L. E., Rao, B. N., Pratt, C. B., Merchant, T. E., Santana, V. M., & Pappo, A. S. (2002) · Cancer · doi:10.1002/cncr.10192 · Cited by 166
Haeusler, J., Ranft, A., Boelling, T., Gosheger, G., Braun‐Munzinger, G., Vieth, V., Burdach, S., van den Berg, H., Juergens, H., & Dirksen, U. (2010) · Cancer · doi:10.1002/cncr.24740 · Cited by 166
Self-citationKushner, B. H., Meyers, P. A., Gerald, W. L., Healey, J. H., La Quaglia, M. P., Boland, P., Wollner, N., Casper, E. S., Aledo, A., & Heller, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2796 · Cited by 163
Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma
Shankar, A., Ashley, S. E., Craft, A. W., et al. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10248 · Cited by 113
Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., Wu, J., & Smith, M. A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22367 · Cited by 97
Ewing sarcoma: prognostic criteria, outcomes and future treatment
Leavey, P. J., & Collier, A. B. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.617 · Cited by 74
Wagner, L. M., Perentesis, J. P., Reid, J. M., Ames, M. M., Safgren, S. L., Nelson, M. D., Ingle, A. M., Blaney, S. M., & Adamson, P. C. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22407 · Cited by 70
McTiernan, A., Cassoni, A. M., Driver, D., Michelagnoli, M. P., Kilby, A. M., & Whelan, J. (2006) · Sarcoma · doi:10.1155/srcm/2006/83548 · Cited by 51
Burdach, S. E. G., Thiel, U., Schöniger, M., Haase, R., Wawer, A., Nathrath, M., Kabisch, H., Urban, C. E., Laws, H. ‐., Dirksen, U., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.184 · Cited by 36
Self-citationDirksen, U., & Jürgens, H. (2010) · Future Oncology · doi:10.2217/fon.10.76 · Cited by 19
Self-citation
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citationEwing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationThe Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K. C., Calicchio, M. L., Kiezun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 566
Metadata
- Authors
- Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., & Dirksen, U.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2011-03-25
- Volume
- 57
- Issue
- 4
- Pages
- 549-553
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2046131550
- Cited by
- 315
- References
- 28
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.